Mechanisms of Disease: sodium channels and neuroprotection in multiple sclerosis - current status

被引:135
作者
Waxman, Stephen G. [1 ,2 ]
机构
[1] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA
[2] VA Connecticut Healthcare, Ctr Neurosci & Regenerat Res, West Haven, CT USA
来源
NATURE CLINICAL PRACTICE NEUROLOGY | 2008年 / 4卷 / 03期
关键词
multiple sclerosis; neuroprotection; sodium channel blockers;
D O I
10.1038/ncpneuro0735
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Sodium channels can provide a route for a persistent influx of sodium ions into neurons. Over the past decade, it has emerged that sustained sodium influx can, in turn, trigger calcium ion influx, which produces axonal injury in neuroinflammatory disorders such as multiple sclerosis (MS). The development of sodium channel blockers as potential neuroprotectants in MS has proceeded rapidly, and two clinical trials are currently ongoing. The route from the laboratory to the clinic includes some complex turns, however, and a third trial was recently put on hold because of new data that suggested that sodium channel blockers might have multiple, complex actions. This article reviews the development of the concept of sodium channel blockers as neuroprotectants in MS, the path from laboratory to clinic, and the current status of research in this area.
引用
收藏
页码:159 / 169
页数:11
相关论文
共 50 条
  • [21] Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels
    Pryce, Gareth
    Sisay, Sofia
    Giovannoni, Gavin
    Selwood, David L.
    Baker, David
    PHARMACEUTICALS, 2023, 16 (07)
  • [22] Neuroprotection in multiple sclerosis: A therapeutic challenge for the next decade
    Van der Walt, Anneke
    Butzkueven, Helmut
    Kolbe, Scott
    Marriott, Mark
    Alexandrou, Estella
    Gresle, Melissa
    Egan, Gary
    Kilpatrick, Trevor
    PHARMACOLOGY & THERAPEUTICS, 2010, 126 (01) : 82 - 93
  • [23] The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update
    Sangha, Amarpreet
    Quon, Michaela
    Pfeffer, Gerald
    Orton, Sarah-Michelle
    NUTRIENTS, 2023, 15 (13)
  • [24] Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research
    Rottlaender, Andrea
    Kuerten, Stefanie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (07) : 14850 - 14865
  • [25] Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases
    Dhib-Jalbut, Suhayl
    Arnold, Douglas L.
    Cleveland, Don W.
    Fisher, Mark
    Friedlander, Robert M.
    Mouradian, M. Maral
    Przedborski, Serge
    Trapp, Bruce D.
    Wyss-Coray, Tony
    Yong, V. Wee
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 176 (1-2) : 198 - 215
  • [26] Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives
    Aktas, Orhan
    Albrecht, Philipp
    Hartung, Hans-Peter
    CURRENT OPINION IN NEUROLOGY, 2016, 29 (03) : 199 - 204
  • [27] Current status and future prospective of immunointervention in multiple sclerosis
    Cavaletti, Guido
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (19) : 2329 - 2343
  • [28] Efficacy and safety of laquinimod in multiple sclerosis: current status
    Haggiag, Shalom
    Ruggieri, Serena
    Gasperini, Claudio
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2013, 6 (06) : 343 - 352
  • [29] Multiple sclerosis in Pakistan: Current status and future perspective
    Shah, Zara
    Wasay, Mohammad
    Chaudhry, Burhan Z.
    Fredrikson, Sten
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 418
  • [30] Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis
    Fernández, O
    JOURNAL OF NEUROLOGY, 2002, 249 (01) : 1 - 8